Search over 3,000 reports

    Microbiome-Competitive Landscape, Technology and Pipeline Analysis, 2017

    Microbiome-Competitive Landscape, Technology and Pipeline Analysis, 2017
    Date: Aug, 2017
    Type: Pharmaceutical Industry Report
    Pages: 280
    Geography: Global
    Delivery Timeline: 24 Hours
    SKU: DISR0003

    DelveInsight's, "Microbiome-Competitive Landscape, Technology and Pipeline Analysis, 2016", report provides comprehensive insights about pipeline drugs across this microbiome based products. This report provides information on the therapeutic development based on the Microbiome dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information.

    There are total 73 drugs in pipeline out of which 2 products is in Phase II/III, 8 products in Phase II, 6 product are in Phase I, 1 product are in Phase 0 and 1 Product in IND. Around 34 products are in Pre-clinical, 18 products are in Discovery stage of development and 3 products is in Unknown stage of development. Companies have also gone in collaboration with different partners.

    The market of microbiome therapies is progressing rapidly. Various companies are getting on the action, aiming to target microbes to treat various types of diseases. Synlogic is currently developing 6 drugs that address disease by targeting gut microbiome using their synthetic biotics approach. The company is also collaborated with different partners to apply their platform to create innovative synthetic biotics for the treatment of major diseases in disease areas including inflammation, metabolism, oncology and CNS. All products of Synlogic are in Pre-Clinical and Discovery stage. Other companies are also in race for developing the products that target the microbes. Seres therapeutics is also developing the 5 products with their lead program, SER-109 for the prevention of recurrent Clostridium difficile infections, which has granted the Breakthrough therapy by FDA.

    The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.
    Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

    Please note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated therapy.

    Executive Summary
    Executive Summary Snapshot
    Microbiome Overview
    Microbiome-Host Interaction
    Human Microbiota Ecosystems
    Role of Microbiota in Health and Disease
    Effects of Probiotics and Prebiotics on gut microbiota
    Microbiome Projects under development
    Future of Microbiome
    Hinderances for Microbiome as therapy
    Challenges in studying the microbiome
    Unmet needs of Microbiome
    Pipeline Products Analysis
    Microbiome-Number of Products (N) and Therapy Area
    Microbiome Analysis by Therapy Area and Companies
    Collaboration with Institutes
    Number of Collaboration with Companies Year Wise
    Number of Collaboration with Institutes Year wise
    Collaboration with Companies
    Collaboration with Institutes/Universities
    Technology
    Designation
    Grants
    Financing
    Pipeline Therapeutics
    Therapeutics under Development by Companies
    Mid Stage Products (Phase II)
    Comparative Analysis
    Early Stage Products (Phase I and IND)
    Comparative Analysis
    Discovery and Pre-clinical stage Products
    Comparative Analysis
    Drug 1
    Product Description
    Research and Development
    Product Development Activities

    Product Description
    Research and Development
    Product Development Activities
    Therapeutic Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Route of Administration
    Assessment by Molecule Type
    Assessment by Stage and Molecule Type
    Companies Planning for Future Development in Microbiome
    Appendix
    DelveInsight Consulting Services
    About DelveInsight
    Contact Us
    Disclaimer
     

    Table 1:Collaboration with Companies, 2017
    Table 2:Collaboration with Institutes/Universities, 2017
    Table 3: Microbiome technologies, 2017
    Table 4: Designation, 2017
    Table 5: Grants, 2017
    Table 6 : Financing, 2017
    Table 7: Number of Products Under Development for Microbiome, 2017
    Table 8: Number of Products under Development by Companies, 2017
    Table 9: Mid Stage Products (Phase II),2017
    Table 10: Early Stage Products (Phase I and IND), 2017
    Table 11: Discovery and Pre-clinical Stage Products , 2017
    Table 12: Number of Products Under Development for Microbiome, 2017
    Table 13: Assessment by Combination Products, 2017
    Table 14: Assessment by Route Of Administration, 2017
    Table 15: Assessment by Stage and Route Of Administration, 2017
    Table 16: Assessment by Molecule Type, 2017
    Table 17: Assessment by Stage and Molecule Type, 2017

    Figure 1: Microbiome-Number of Products (N) and with Therapy Area, 2017
    Figure 2: Number of Collaborations with Institute and Company, 2017
    Figure 3: Number of Collaboration of Company, 2017
    Figure 4: Number of Collaboration of Institute, 2017
    Figure 5: Microbiome, number products and technology, 2017
    Figure 6: Number of products and designation, 2017
    Figure 7: Designation and year, 2017
    Figure 8: Grants, 2017
    Figure 9: Financing, 2017
    Figure 10: Financing, 2017
    Figure 11: Number of Products under Development for Microbiome, 2017
    Figure 12: Mid Stage Products (Phase II), 2017
    Figure 13: Early Stage Products (Phase I and IND), 2017
    Figure 14: Discovery and Pre-clinical Stage Products, 2017
    Figure 15: Assessment by Monotherapy Products,2017
    Figure 16: Assessment Combination Products, 2017
    Figure 17: Assessment by Route of Administration, 2017
    Figure 18: Assessment by Stage and Route of Administration, 2017
    Figure 19: Assessment by Molecule Type, 2017
    Figure 20:Assessment by Stage and Molecule Type, 2017

    Therapy Pipeline scenario
    Current Prominent Research Areas and Key Players
    Collaborations details and Deal values
    Technologies and Targeted antigens
    Pipeline product profiles, Technologies
    Licensing opportunities
    Market Drivers and Barriers
    SWOT Analysis
    • Single User License
      $3,250.00
    • Site License
      $6,500.00
    • Global License
      $9,750.00

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap